Author Page for Ann M. Buchanan

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Dolutegravir Dispersible Tablets in Infants and Children with HIV-1: Results of the IMPAACT P1093 Study, a Phase I/II Open-Label Trial

Number of pages: 24 Posted: 10 Nov 2021

Theodore Dumont Ruel, Edward P. Acosta, Jessica P. Liu, Kathryn P. Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M. Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech, Tichaona Vhembo, Rohan Hazra, Ellen Townley, Andrew Wiznia and IMPAACT P1093 Team

University of California, San Francisco (UCSF), University of Alabama at Birmingham, Frontier Science & Technology Research Foundation, Harvard T.H. Chan School of Public Health, FHI 360, FHI 360, Frontier Science & Technology Research Foundation, ViiV Healthcare Ltd., Frontier Science & Technology Research Foundation, University of California, Los Angeles (UCLA), University of Southern California, ViiV Healthcare Ltd., ViiV Healthcare Ltd., ViiV Healthcare Ltd., Kenya Medical Research Institute (KEMRI) - Kenya Medical Research Institute (KEMRI)/Walter Reed Project, University of Zimbabwe, Government of the United States of America - Eunice Kennedy-Shriver National Institutes of Child Health and Human Development, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Yeshiva University - Jacobi Medical Center and Independent

Downloads 67 (899,324)

Citation 3

Ann M. Buchanan

ViiV Healthcare Ltd.

1

67

3

Scholarly Papers (1)

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Dolutegravir Dispersible Tablets in Infants and Children with HIV-1: Results of the IMPAACT P1093 Study, a Phase I/II Open-Label Trial

Abstract: